# ulcerative colitis (UC) - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 3994
- Completion tokens: 4928
- Reasoning tokens: 
- Total tokens: 8922
- API requests reported: 
- Elapsed seconds: 92.201
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: OpenAI

---
## 1. Overall biological interpretation

The UC mucosal transcriptome shows a strong, statistically robust shift from a homeostatic absorptive epithelial state toward an inflamed, injured, antimicrobial, and remodeling state.

The dominant signal is not a single pathway but a coordinated tissue response involving:

- **Innate inflammatory recruitment and myeloid-associated signaling**, including marked increases in **S100A8, CXCL1, CXCL2, CXCL3, CHI3L1, PLA2G2A, IL1RN, SOCS3, IRAK3, and MMP3**.
- **Epithelial antimicrobial and oxidative defense**, represented by **DUOX2, DUOXA2, LCN2, PI3, and REG4**.
- **Epithelial injury, regeneration, extracellular-matrix remodeling, and stromal activation**, including **TNC, PDPN, PRRX1, TGM2, SERPINB5, CDH3, and MMP3**.
- **Loss of differentiated epithelial transport and metabolic functions**, with decreased **AQP8, SLC23A1, SLC16A1, SLC51A, ABCG2, HMGCS2, G6PC, SLC38A4, and MEP1B**.
- Possible **changes in immune-cell composition or activation**, suggested by increased immunoglobulin transcripts, **CTLA4, DAPP1, IFI16, and CD55**.

All listed genes pass the reported FDR threshold, many by extremely large margins. However, the biological interpretation remains association-based. In bulk colonic mucosa, altered cellular composition, epithelial loss, inflammatory-cell influx, treatment exposure, and disease severity can produce much of this pattern without implying that every differentially expressed gene is causally pathogenic.

---

## 2. Core biological programs

### Program 1: Innate inflammatory recruitment and myeloid-associated activation

**Direction:** Upregulated in UC.

**Major supporting genes:**  
**S100A8, CXCL1, CXCL2, CXCL3, CHI3L1, PLA2G2A, IL1RN, SOCS3, IRAK3, MMP3, LCN2**

**Appropriate standardized pathways/terms:**

- Hallmark **Inflammatory Response**
- Hallmark **TNFα Signaling via NF-κB**
- Reactome **Cytokine Signaling in Immune System**
- GO **chemokine activity**, **neutrophil chemotaxis**, and **innate immune response**

**Interpretation:**  
The coordinated elevation of three related CXC chemokines—**CXCL1, CXCL2, and CXCL3**—supports active recruitment or retention of neutrophil-like and other myeloid populations. **S100A8** is consistent with inflammatory myeloid-cell abundance or activation, while **CHI3L1, PLA2G2A, LCN2, and MMP3** support a broader inflammatory and tissue-injury phenotype. **IL1RN, SOCS3, and IRAK3** are negative-feedback or tolerance-associated regulators, suggesting that inflammatory activation is accompanied by counter-regulatory signaling rather than representing an unopposed cytokine response.

**Evidence strength:** **Strong for an inflammatory mucosal state.** The evidence is directly supported by multiple highly significant, concordant genes and by coherent pathway-level biology. The precise cellular source is less certain because bulk tissue data cannot separate epithelial, neutrophil, macrophage, and stromal contributions.

**Main limitations:** Chemokine and S100A8 expression may primarily reflect infiltrating cells rather than transcriptional activation within epithelial cells. The dataset does not establish which upstream cytokines or receptors drive the program.

---

### Program 2: Epithelial antimicrobial and oxidative defense

**Direction:** Upregulated in UC.

**Major supporting genes:**  
**DUOX2, DUOXA2, LCN2, PI3, REG4, DEFB1** *(with DEFB1 decreased in this dataset)*

**Appropriate standardized pathways/terms:**

- GO **response to oxidative stress**
- GO **antimicrobial humoral response**
- GO **defense response to bacterium**
- Reactome **Innate Immune System**
- Hallmark **Reactive Oxygen Species Pathway**

**Interpretation:**  
The strong induction of **DUOX2** together with its activating partner **DUOXA2** is consistent with enhanced epithelial hydrogen-peroxide-generating capacity. **LCN2**, **PI3**, and **REG4** are compatible with epithelial antimicrobial, secretory, or injury-response states. This suggests that UC mucosa is attempting to reinforce host defense at the epithelial surface, potentially in response to barrier disruption and altered microbial exposure.

The decrease in **DEFB1** is important and argues against a uniformly increased antimicrobial program. It may indicate selective rather than global antimicrobial remodeling, cell-type differences, or disease-state heterogeneity.

**Evidence strength:** **Strong for epithelial defense remodeling**, particularly because DUOX2 and DUOXA2 are directionally concordant. Evidence for a uniformly enhanced antimicrobial barrier is weaker because **DEFB1 is downregulated** and no microbiome or functional antimicrobial assay is provided.

**Main limitations:** Oxidative defense may be protective, damaging, or both. Increased DUOX2 expression does not prove increased enzymatic activity or that reactive oxygen species are causing tissue injury.

---

### Program 3: Epithelial injury, regeneration, extracellular-matrix remodeling, and stromal activation

**Direction:** Upregulated in UC.

**Major supporting genes:**  
**MMP3, TNC, PDPN, PRRX1, TGM2, SERPINB5, CDH3, TRIM29, TIMP1, FILIP1L**

**Appropriate standardized pathways/terms:**

- GO **extracellular matrix organization**
- GO **wound healing**
- Reactome **Degradation of the Extracellular Matrix**
- Reactome **Collagen formation and extracellular matrix organization**
- Hallmark **Epithelial-Mesenchymal Transition**

**Interpretation:**  
The combination of **MMP3** and **TNC** indicates matrix turnover and tissue remodeling, while **TIMP1** suggests simultaneous induction of matrix-protective or inhibitory responses. **PDPN** and **PRRX1** may reflect activated stromal or mesenchymal populations, whereas **CDH3, SERPINB5, TRIM29, and TGM2** are compatible with epithelial stress, altered differentiation, and regenerative remodeling. This profile is consistent with repeated mucosal injury and repair rather than with a purely inflammatory process.

**Evidence strength:** **Moderate to strong for remodeling and repair.** Multiple matrix, epithelial-stress, and wound-associated genes are concordant. The assignment of individual genes to epithelial versus stromal compartments is uncertain.

**Main limitations:** A Hallmark EMT annotation can be nonspecific in inflamed mucosa and should not be interpreted as proof of epithelial-to-mesenchymal transition. The data do not distinguish productive healing from maladaptive fibrosis or chronic remodeling.

---

### Program 4: Loss of differentiated epithelial transport and metabolic functions

**Direction:** Downregulated in UC.

**Major supporting genes:**  
**AQP8, AQP7, SLC23A1, SLC23A3, SLC16A1, SLC38A4, SLC51A, ABCG2, HMGCS2, G6PC, MEP1B, SLC19A3**

**Appropriate standardized pathways/terms:**

- GO **transmembrane transport**
- GO **water transport**
- GO **organic anion and solute transport**
- GO **cellular metabolic process**
- Hallmark **Oxidative Phosphorylation** or **Fatty Acid Metabolism** only if supported by broader gene-set analysis; the current gene list alone is insufficient for a definitive Hallmark assignment

**Interpretation:**  
The simultaneous decrease of aquaporins, nutrient and metabolite transporters, bile-acid-related transport machinery, brush-border peptidase **MEP1B**, and metabolic genes such as **HMGCS2** and **G6PC** indicates reduced mature absorptive epithelial function. This is compatible with epithelial dedifferentiation, crypt remodeling, loss of mature colonocyte populations, or functional suppression during inflammation.

**Evidence strength:** **Strong for reduced expression of absorptive/transport-associated genes**, because many independent transport and metabolic genes move in the same direction. The functional consequence is a **supported hypothesis**, not directly measured physiology.

**Main limitations:** This program may largely represent altered epithelial cell composition. Reduced expression could reflect loss of differentiated epithelial cells rather than reversible suppression within surviving cells.

---

### Program 5: Immune-cell representation and adaptive immune modulation

**Direction:** Upregulated in UC, with evidence of possible composition effects.

**Major supporting genes:**  
**CTLA4, DAPP1, IFI16, CD55, immunoglobulin-containing transcript(s), UBD|GABBR1**

**Appropriate standardized pathways/terms:**

- GO **adaptive immune response**
- GO **T-cell activation**
- Reactome **Immune System**
- GO **immunoglobulin production**

**Interpretation:**  
Increased **CTLA4** is compatible with activated or regulatory T-cell populations, while **DAPP1** is associated with signaling in hematopoietic cells. The immunoglobulin-containing transcript suggests increased B-cell or plasma-cell representation, although the composite annotation prevents precise interpretation. **IFI16** and **CD55** indicate immune and inflammatory regulation but are not specific to one immune lineage.

**Evidence strength:** **Moderate for increased immune representation or activation.** The evidence is based on several immune-associated genes, but it is less specific than the chemokine signal. In bulk mucosa, increased immunoglobulin or CTLA4 expression may primarily indicate greater immune-cell abundance.

**Main limitations:** No cell deconvolution, flow cytometry, histology, or single-cell data are available. It is not possible to determine whether CTLA4 reflects regulatory T cells, activated conventional T cells, or other CTLA4-expressing populations.

---

## 3. Key genes and interaction modules

The following candidates are prioritized as modules or representative genes rather than isolated disease markers.

| Candidate | Current result | Potential role | Nature of relationship/evidence |
|---|---:|---|---|
| **DUOX2–DUOXA2 module** | DUOX2 +4.67; DUOXA2 +2.89 | Epithelial oxidative and antimicrobial defense | **Direct functional partnership**: DUOXA2 is a known activator of DUOX2. The dataset provides strong co-directional expression evidence; it does not prove increased ROS production. |
| **CXCL1–CXCL2–CXCL3 module** | +3.46, +2.80, +2.33 | Neutrophil/myeloid recruitment and inflammatory amplification | **Pathway co-membership and likely shared regulation**, not direct physical interaction. The concordance of three chemokines is stronger than any single gene. |
| **S100A8–LCN2–CHI3L1 inflammatory module** | +3.80, +2.67, +4.59 | Myeloid-associated inflammation, epithelial injury, and innate defense | **Indirect/putative relationship and co-occurrence in inflammatory tissue**. Cellular source should be resolved experimentally. |
| **MMP3–TNC–TIMP1 remodeling module** | MMP3 +4.64; TNC +2.58; TIMP1 +1.97 | Matrix turnover, wound repair, and chronic tissue remodeling | **Pathway co-membership and regulatory balance**; not evidence of direct physical interaction among all three genes. |
| **AQP8–AQP7 transport module** | AQP8 −4.42; AQP7 −2.32 | Water handling and differentiated epithelial physiology | **Pathway co-membership and shared epithelial-state dependence**. Their coordinated loss supports altered epithelial function but not a direct interaction. |
| **SLC transporter module** | SLC38A4, SLC23A1/3, SLC16A1, SLC51A, ABCG2 all decreased | Nutrient, metabolite, bile-acid, and xenobiotic transport | **Functional/pathway co-membership**, not direct interaction. The breadth of the signal supports loss of mature epithelial transport identity. |
| **HMGCS2–G6PC metabolic module** | HMGCS2 −3.45; G6PC −1.52 | Colonocyte metabolic specialization and epithelial energy handling | **Metabolic pathway relationship**. The dataset supports reduced expression, not a specific metabolic flux defect. |
| **CTLA4–DAPP1–immunoglobulin module** | CTLA4 +2.62; DAPP1 +2.20; immunoglobulin transcript +1.89 | Increased immune-cell representation and adaptive immune modulation | **Cellular co-occurrence/pathway association**. There is no evidence here for a direct CTLA4–DAPP1 physical interaction. |
| **REG4–PI3–DEFB1 epithelial defense module** | REG4 +2.05; PI3 +2.21; DEFB1 −2.31 | Secretory and antimicrobial epithelial remodeling | **Functional co-membership**, with internally conflicting direction because DEFB1 is reduced. This is a heterogeneous defense response rather than a uniformly induced module. |

Additional notable genes include **SLC6A14** (+4.85), **SERPINB5** (+3.29), **VNN1** (+3.20), **TRIM29** (+2.83), and **SOCS3** (+2.79). Their large effects make them attractive follow-up markers, but the present table does not establish whether they are central regulators or downstream indicators of altered cell composition and mucosal stress.

---

## 4. High-priority validation directions

### 1. DUOX2–DUOXA2 oxidative-defense axis

**Classification:** Mechanistic hypothesis

**Why prioritize:**  
It is one of the most internally coherent epithelial modules, with strong induction of both the oxidase and its activating partner.

**Current evidence:**  
Very large and highly significant increases in **DUOX2** and **DUOXA2**, supported by concurrent induction of other epithelial defense genes such as **LCN2** and **PI3**.

**External evidence:**  
The DUOX2/DUOXA2 system is biologically established as an epithelial reactive-oxygen-generating system and has been implicated in intestinal host defense and inflammatory mucosal states. This supports biological plausibility but does not prove that it is pathogenic in these samples.

**Next step:**  
Use UC and control organoids or primary epithelial cultures to measure DUOX2 protein, hydrogen peroxide generation, microbial killing, and epithelial injury. Perturb DUOX2 or DUOXA2 genetically or pharmacologically and assess barrier and inflammatory outputs.

**Conclusion level:** **Supported hypothesis**, not causal proof.

---

### 2. Inflammatory chemokine–myeloid recruitment module

**Classification:** Biomarker and interaction/network hypothesis

**Why prioritize:**  
**CXCL1, CXCL2, CXCL3, S100A8, CHI3L1, and LCN2** form a strong inflammatory signature with potential relevance to disease activity and mucosal inflammatory burden.

**Current evidence:**  
Multiple concordant genes with large effect sizes and very low FDR values.

**External evidence:**  
These genes are broadly associated with intestinal inflammation and neutrophil/myeloid responses. However, their expression can be driven by infiltrating cells and therefore may reflect severity rather than a disease-specific mechanism.

**Next step:**  
Validate in an independent cohort, correlate with endoscopic and histologic activity, and localize expression by single-cell RNA-seq, spatial transcriptomics, or multiplex immunostaining. Measure tissue or stool protein levels where feasible.

**Conclusion level:** **Supported hypothesis** for a tissue inflammatory biomarker; insufficient evidence to assign causality to any one chemokine.

---

### 3. Loss of differentiated absorptive epithelial identity

**Classification:** Confounding or composition check, with mechanistic implications

**Why prioritize:**  
The coordinated decrease of transporters, aquaporins, brush-border enzymes, and metabolic genes may be central to mucosal dysfunction but could also be a compositional artifact.

**Current evidence:**  
Strong downregulation of **AQP8, AQP7, SLC23A1, SLC16A1, SLC51A, ABCG2, HMGCS2, G6PC, SLC38A4, and MEP1B**.

**External evidence:**  
Mature colonocytes and absorptive epithelial cells are known to express specialized transporter and metabolic programs, and these programs can be altered in inflamed intestine. Nevertheless, bulk tissue expression cannot distinguish reduced per-cell expression from fewer mature epithelial cells.

**Next step:**  
Perform cell-type deconvolution and validate with epithelial-subtype markers, histology, and single-cell or spatial profiling. In organoids, test whether inflammatory cytokines suppress these genes in otherwise preserved mature epithelial cells.

**Conclusion level:** **Established evidence for differential expression; supported but unresolved interpretation regarding functional epithelial loss.**

---

### 4. MMP3–TNC matrix-remodeling and repair response

**Classification:** Mechanistic hypothesis and biomarker

**Why prioritize:**  
The strong induction of **MMP3** and **TNC**, together with **TIMP1, PDPN, PRRX1, and TGM2**, suggests a substantial wound-repair and stromal-remodeling component.

**Current evidence:**  
Concordant expression of matrix-turnover, stromal, and epithelial-stress genes.

**External evidence:**  
Matrix remodeling and repair responses are well documented in inflamed mucosa. However, MMP3 or TNC elevation may be downstream consequences of injury and does not establish that they initiate UC pathology.

**Next step:**  
Localize the transcripts and proteins to epithelial, fibroblast, and immune compartments; assess matrix deposition and protease activity; correlate with healing versus persistent ulceration. Functional perturbation should be performed only after cell sources are established.

**Conclusion level:** **Supported hypothesis.**

---

### 5. Immune composition and CTLA4/immunoglobulin signal

**Classification:** Confounding or composition check

**Why prioritize:**  
The increase in **CTLA4**, **DAPP1**, and immunoglobulin-containing transcripts could represent biologically important adaptive immune activation, but it could also simply reflect greater lymphocyte or plasma-cell abundance in UC mucosa.

**Current evidence:**  
Upregulation of several immune-associated signals, including CTLA4 and immunoglobulin transcripts.

**External evidence:**  
UC lesions commonly contain expanded and activated immune populations. CTLA4 expression is not specific for a single T-cell state, and immunoglobulin transcripts are strongly dependent on plasma-cell abundance.

**Next step:**  
Apply bulk RNA deconvolution and validate with flow cytometry or single-cell/spatial profiling for T-cell, regulatory T-cell, B-cell, and plasma-cell populations. Relate the signal to treatment exposure and disease activity.

**Conclusion level:** **Exploratory hypothesis regarding immune mechanism; stronger evidence for altered cellular composition than for a specific CTLA4-mediated mechanism.**

---

## 5. Limitations and alternative explanations

1. **Cellular composition is a major potential confounder.**  
   Increased inflammatory and immune-cell abundance can explain **S100A8, CXCLs, CTLA4, DAPP1, immunoglobulin transcripts, CHI3L1, and possibly LCN2**. Loss of mature epithelial cells can explain decreased transport and metabolic genes. Single-cell, spatial, flow-cytometric, or histologic validation is needed.

2. **Disease severity, ulceration, and treatment exposure are not provided.**  
   Severe active UC is expected to show stronger chemokine, antimicrobial, matrix-remodeling, and epithelial-loss signatures than mild disease. Corticosteroids, biologics, 5-aminosalicylates, and other treatments could alter these pathways.

3. **Bulk transcriptomics cannot establish cellular origin or causality.**  
   Increased expression may be downstream of cytokine exposure, tissue damage, or repair. Perturbation experiments and protein/activity measurements are required before assigning causal roles.

4. **Several biological programs are broad and potentially overlapping.**  
   “Inflammation,” “wound healing,” and “epithelial stress” share many genes. Pathway labels should therefore be supported by formal enrichment, leading-edge analysis, and cell-type localization rather than by gene-name interpretation alone.

5. **Annotation and platform limitations may affect interpretation.**  
   Composite or unannotated features such as **LOC100290146|IGHV4-31|IGHM|IGHG1|IGH**, **UBD|GABBR1**, and probe-only identifiers require transcript-level verification. Repeated entries for **CYP2B6/CYP2B7P** and **NAT8/NAT8B** may reflect probe or annotation structure rather than independent biological signals.

Overall, the most defensible interpretation is that UC mucosa exhibits **active innate inflammation and epithelial defense remodeling together with impaired differentiated epithelial transport and substantial tissue repair/matrix remodeling**. The inflammatory and epithelial-state conclusions are strongly supported by the supplied statistics; the causal importance of individual genes and the contribution of altered cellular composition remain to be resolved.
